human
respiratori
syncyti
viru
rsv
infect
common
caus
hospit
lower
respiratori
tract
infect
ltri
children
five
year
age
worldwid
sever
rsv
diseas
occur
extrem
age
rsv
lead
caus
death
due
ltri
children
six
month
age
among
elderli
patient
rsv
infect
also
major
caus
hospit
associ
death
usa
thu
develop
effect
rsv
vaccin
substanti
import
live
vaccin
smallpox
vaccin
pioneer
jenner
provid
immun
may
safeti
risk
inactiv
vaccin
gener
safer
formalininactiv
rsv
vaccin
adjuv
alum
evalu
healthi
infant
young
children
vaccine
infect
requir
hospit
compar
control
group
consider
effort
direct
toward
develop
subunit
base
rsv
vaccin
design
elicit
potent
neutral
antibodi
target
specif
epitop
rsv
f
g
surfac
protein
well
chimer
fg
variant
use
immunogen
result
robust
albeit
poorli
neutral
antibodi
subunit
vaccin
approach
explor
purifi
protein
vectorbas
format
vaccin
approach
base
solubl
protein
gener
poorli
immunogen
usual
requir
adjuv
augment
immunogen
number
synthet
natur
compound
identifi
adjuv
activ
howev
includ
alum
squalen
oilinwat
monophosphoryl
lipid
mpla
achiev
widespread
human
use
adjuv
either
activ
pattern
recognit
receptor
prr
tolllik
receptor
tlr
innat
immun
system
improv
deliveri
antigen
immun
system
common
adjuv
alum
compris
aluminum
salt
use
human
sinc
approv
human
use
fda
compon
numer
licens
vaccin
diphtheria
tetanu
pertussi
dtap
vaccin
hepat
b
vaccin
mpla
alum
use
hepat
b
vaccin
fendrix
human
papillomaviru
hpv
vaccin
cervarix
extens
human
safeti
data
context
oilinwat
formul
compon
fluad
new
season
flu
vaccin
elderli
mpla
also
compon
pollinex
quattro
vaccin
use
treatment
season
allerg
rhiniti
combin
polyanion
carbom
well
adjuplex
coformul
carbom
lecithin
potent
welltoler
adjuv
administ
subunit
vaccin
carbom
also
evalu
experiment
adjuv
veterinari
vaccin
swine
parvoviru
circoviru
type
staphylococcu
aureu
sheep
equin
influenza
viru
poli
c
synthet
doublestrand
rna
deriv
poli
ic
lc
report
rang
anim
speci
mice
nonhuman
primat
reveal
signific
enhanc
immunogen
cancer
immunotherapi
clinic
trial
compon
intranas
flu
vaccin
flumist
montanid
famili
oilbas
adjuv
use
produc
emuls
antigen
interest
use
experiment
vaccin
mice
rat
dog
cat
use
natur
recombin
synthet
antigen
montanid
use
worldwid
bovin
ovin
vaccin
viral
bacteri
parasit
diseas
human
montanid
emuls
use
experiment
human
vaccin
hiv
malaria
breast
cancer
adjuv
uniqu
characterist
mechan
impact
immun
respons
induc
particular
immunogen
gener
need
determin
experiment
previous
engin
prefus
stabil
trimer
rsv
f
pref
immunogen
name
adjuv
agonist
poli
c
poli
ic
lc
induc
high
neutral
antibodi
titer
mice
nonhuman
primat
respect
herein
report
compar
adjuv
studi
formul
nine
differ
adjuv
tabl
mice
also
studi
elderli
mice
preimmun
adjuv
poli
c
evalu
impact
carbopol
mice
calv
use
bovin
rsv
f
version
result
indic
adjuv
requir
induc
high
titer
respons
moder
high
titer
respons
induc
adjuv
test
optim
respons
adjuv
appear
contextdepend
eg
whether
anim
preexist
respons
speciesspecif
eg
addit
carbopol
induc
high
respons
mice
calv
alhydrogel
alum
purchas
brenntag
denmark
addavax
monophosphoryl
lipid
asm
mpla
poli
c
purchas
invivogen
sigma
adjuv
system
sa
adjuplex
purchas
sigmaaldrich
carbopol
gift
mutchler
inc
poli
ic
lc
gift
salazar
oncovir
dc
montanid
isa
vg
gift
seppic
franc
cell
purchas
thermo
fisher
scientif
ni
sepharos
excel
streptactin
superflow
resin
purchas
ge
healthcar
iba
respect
restrict
grade
thrombin
obtain
novagen
cell
purchas
atcc
va
rsv
f
rsv
f
site
site
ii
knockout
ko
protein
express
transient
transfect
cell
use
cultur
supernat
harvest
day
post
transfect
centrifug
g
remov
cell
debri
supernat
sterilefilt
rsv
f
purifi
nickel
streptactinaffin
chromatographi
follow
sizeexclus
chromatographi
use
superdex
column
ge
healthcar
streptactin
purif
tag
remov
rsv
f
protein
digest
restrictiongrad
biotinyl
thrombin
novagen
overnight
cleav
rsv
f
purifi
sizeexclus
chromatographi
sec
phosphatebuff
salin
pb
prior
immun
bovin
rsv
f
express
purifi
analog
specif
bovin
rsv
f
express
transient
transfect
cell
use
purifi
use
imac
streptactin
affin
sizeexclus
chromatographi
mous
experi
review
approv
anim
care
use
committe
vaccin
research
center
niaid
nih
anim
protocol
identif
number
anim
hous
care
accord
local
state
feder
institut
polici
american
associ
accredit
laboratori
anim
care
aaalac
accredit
facil
nih
calf
experi
perform
regul
unit
kingdom
home
offic
scientif
procedur
act
studi
review
approv
anim
plant
health
agenc
apha
ethic
review
committe
femal
hybrid
mice
use
studi
first
filial
offspr
cross
balbcj
femal
c
male
jackson
laboratori
mice
use
earlier
rsv
immunogen
experi
provid
increas
genet
complex
flexibl
allow
direct
comparison
prior
result
mice
age
week
inject
rsv
f
mixtur
week
zero
week
three
homolog
primeboost
semimembranosu
muscl
pelvic
limb
rsv
f
immunogen
without
adjuv
immun
given
intramuscularli
anim
receiv
total
pb
contain
rsv
f
immunogen
inocul
vv
mixtur
sigma
adjuv
system
sa
sigma
sa
group
inocul
fold
ww
poli
c
poli
c
group
inocul
fold
ww
poli
ic
lc
poli
ic
lc
group
inocul
fold
ww
monophosphoryl
lipid
mpla
group
inocul
fold
ww
alum
alum
group
inocul
vv
mixtur
sigma
adjuv
system
plu
ng
wv
carbopol
sa
carbopol
group
inocul
vv
addavax
addavax
group
inocul
vv
adjuplex
adjuplex
group
inocul
fold
ww
monophosphoryl
lipid
plu
fold
ww
alum
mpla
alum
group
inocul
formul
within
one
hour
immun
follow
mix
immedi
prior
inject
control
group
adjuv
also
includ
studi
advers
effect
immun
observ
studi
anim
sera
sampl
collect
least
three
day
immun
two
week
immun
indic
time
point
anim
experi
conduct
full
complianc
relev
feder
regul
nih
guidelin
elderli
mice
studi
two
group
seven
mice
preimmun
multipl
time
poli
c
formul
immun
twice
formul
alum
sa
carbopol
wait
period
week
mice
two
inject
site
semimembranosu
muscl
pelvic
limb
use
immun
advers
effect
immun
observ
sera
collect
least
three
day
immun
week
two
week
five
post
initi
immun
brsv
seroneg
male
calv
produc
describ
previous
vaccin
intramuscularli
brsv
f
adjuv
mixtur
volum
ml
two
occas
week
apart
calv
week
age
time
vaccin
five
calv
vaccin
brsv
f
emulsifi
montanidetm
isa
vg
seppic
franc
water
oil
emuls
ratio
adjuv
aqueou
phase
describ
previous
two
calv
vaccin
brsv
f
plu
carbopol
vv
emulsifi
montanidetm
isa
vg
vv
calv
develop
either
mild
swell
inject
site
transient
fever
h
vaccin
sera
collect
one
two
weekli
interv
vaccin
viral
stock
prepar
maintain
previous
describ
recombin
mkatersv
express
prototyp
subtyp
strain
f
gene
katushka
fluoresc
protein
construct
report
hotard
et
al
cell
atcc
va
maintain
eagl
minim
essenti
medium
contain
fetal
bovin
serum
emem
supplement
glutamin
penicillin
streptomycin
neutral
antibodi
measur
fluoresc
plate
reader
neutral
assay
x
cellswel
cultur
medium
seed
black
optic
bottom
plate
plate
thermo
scientif
west
palm
beach
fl
palivizumab
dose
concentr
mgkg
serum
level
trough
provid
protect
infant
sever
diseas
protect
cotton
rat
rsv
infect
neutral
assay
palivizumab
yield
serum
sampl
dilut
fourfold
dilut
start
equal
volum
recombin
mkatersv
ad
mix
incub
one
hour
incub
mixtur
sampl
viru
ad
cellswel
plate
incub
hour
incub
assay
plate
analyz
fluoresc
intens
micropl
reader
excit
wavelength
nm
emiss
wavelength
nm
spectramax
paradigm
molecular
devic
sunnyval
ca
neutral
sampl
calcul
curv
fit
use
graphpad
prism
softwar
graphpad
softwar
inc
san
diego
ca
brsv
microneutr
assay
perform
use
tissu
cultur
infecti
dose
brsv
strain
atcc
bt
cell
atcc
briefli
immun
sera
serial
dilut
quadrupl
prior
mix
brsv
h
humidifi
atmospher
prior
addit
monolay
bt
cell
seed
day
cellswel
cell
incub
day
fix
methanol
stain
crystal
violet
examin
microscop
syncytia
format
cytopath
effect
cpe
neutral
titer
defin
reciproc
highest
sera
dilut
infect
brsv
complet
neutral
well
infect
identifi
presenc
cpe
syncytia
day
titer
calcul
reed
muench
method
octet
instrument
use
measur
sera
recognit
antigen
site
ko
antigen
site
ii
ko
rsv
post
f
rsv
post
f
site
ii
ko
protein
probe
antigen
site
site
ii
motavizumab
target
antibodi
seri
scout
experi
differ
sera
dilut
buffer
condit
sensor
tip
perform
minim
nonspecif
bind
optimum
nonspecif
bind
obtain
use
sensor
tip
sera
dilut
rang
pb
supplement
bsa
initi
assay
use
sera
group
mice
immun
adjuv
formul
well
preble
sera
three
prefus
specif
two
post
fusion
specif
probe
perform
tilt
black
plate
geiger
bioon
agit
set
rpm
pb
supplement
bsa
well
volum
experi
perform
duplic
includ
mice
sampl
per
group
base
sera
avail
ko
post
f
ko
probe
immobil
biosensor
tip
equilibr
bsapb
prior
measur
associ
sera
dilut
bsapb
variabl
load
within
row
eight
tip
exceed
nm
step
parallel
correct
subtract
systemat
baselin
drift
carri
subtract
measur
record
load
sensor
incub
pb
bsa
associ
record
similar
assay
use
measur
sera
reactiv
two
group
preimmun
mice
week
post
immun
well
two
boost
post
f
site
ko
site
ii
ko
post
f
site
ii
ko
probe
data
analysi
perform
use
octet
graphpad
prism
softwar
maxisorp
plate
nunc
well
coat
pb
overnight
plate
wash
block
incub
serial
dilut
mous
sera
differ
group
preble
sera
group
includ
neg
control
antimous
hors
radish
peroxidas
use
secondari
antibodi
tmb
use
substrat
detect
rsv
f
specif
antibodi
respons
endpoint
titer
calcul
highest
serum
dilut
gave
optic
densiti
exceed
five
time
background
elisa
perform
duplic
includ
mice
sampl
per
group
base
sera
avail
endpoint
titer
averag
analyz
use
graphpad
prism
softwar
similar
assay
perform
duplic
use
measur
igg
respons
two
group
seven
elderli
mice
week
post
immun
well
two
post
boost
post
boost
time
point
endpoint
titer
averag
analyz
use
graphpad
prism
softwar
mixtur
use
immun
group
mice
group
formul
nine
differ
adjuv
inject
intramuscularli
twice
interv
three
week
fig
two
immun
week
five
sera
significantli
higher
neutral
titer
observ
mice
immun
adjuv
alum
agonist
poli
c
poli
ic
lc
agonist
sa
sa
carbopol
polyanion
high
molecular
weight
acryl
acid
adjuplex
adjuv
base
purifi
lecithin
carbom
homopolym
geometr
mean
titer
respect
adjuv
agonist
mpla
alum
plu
mpla
addavax
geometr
mean
titer
respect
fig
neutral
titer
control
unadjuv
protect
threshold
level
detect
fig
titer
adjuv
combin
sa
agonist
carbopol
higher
observ
lowest
neutral
group
repres
adjuv
alum
plu
mpla
p
four
fivefold
higher
adjuv
alum
p
agonist
poli
c
p
poli
ic
lc
p
respect
interestingli
agonist
mpla
formul
alum
help
elicit
high
neutral
titer
convers
agonist
present
compon
sa
sa
carbopol
adjuv
help
elicit
highest
immun
respons
among
nine
adjuv
group
understand
higher
neutral
titer
delin
role
adjuv
immunogen
investig
whether
sera
reactiv
direct
toward
prefus
specif
antigen
site
antigen
site
ii
present
preand
postfus
form
rsv
f
protein
fig
explor
sitespecif
immun
respons
aid
probe
ko
mutat
antigen
site
b
post
f
probe
ko
mutat
antigen
site
ii
initi
measur
bind
week
sera
post
f
site
ko
site
ii
ko
post
f
site
ii
ko
probe
use
biolay
interferometri
sera
reactiv
five
group
correspond
poli
c
poli
ic
lc
sa
sa
carbopol
adjuplex
show
greatest
respons
follow
addavax
alum
sera
correspond
mpla
mpla
plu
alum
exhibit
lowest
bind
respons
fig
furthermor
sera
group
exhibit
reduc
bind
site
ko
fig
prefus
specif
site
ko
probe
bound
significantli
less
sera
poli
c
poli
ic
lc
sa
sa
carbopol
adjuplex
adjuv
group
rel
p
respect
demonstr
five
adjuv
could
facilit
robust
respons
antigen
site
contrast
signific
differ
observ
sera
alum
mpla
mpla
alum
addavax
group
fig
indic
adjuv
unabl
enhanc
immun
respons
antigen
site
examin
sera
respons
antigen
site
probe
site
ii
knockout
post
f
site
ii
knockout
probe
demonstr
neutral
antibodi
respons
focus
prefus
specif
antigen
site
display
rsv
f
next
analyz
sera
qualiti
humor
respons
induc
differ
adjuv
formul
found
elicit
differ
igg
subclass
respons
pattern
fig
formul
mpla
alum
plu
mpla
addavax
adjuplex
induc
respons
detect
respons
hand
formul
alum
induc
primarili
respons
formul
sa
sa
carbopol
poli
c
poli
ic
lc
induc
respons
unadjuv
induc
margin
respons
detect
respons
igg
subclass
respons
pattern
appear
determin
properti
adjuv
also
protein
adjuv
formul
subclass
respons
reflect
respect
helper
cell
helper
cell
bias
immun
respons
pattern
mice
slight
domin
respons
elicit
unadjuv
like
due
stimul
bias
respons
mice
although
mpla
known
augment
bias
respons
mpla
mpla
alum
adjuv
formul
suffici
influenc
igg
respons
toward
phenotyp
adjuplex
addavax
suffici
influenc
igg
respons
toward
expect
balanc
respons
expect
alum
adjuv
formul
stimul
primarili
expect
respons
alum
alon
ratio
indic
significantli
greater
respons
adjuv
alum
mpla
adjuplex
p
poli
c
poli
ic
lc
sa
sa
carbopol
gave
balanc
respons
fig
mixtur
use
immun
two
group
elderli
mice
group
elderli
mice
preimmun
prior
week
age
c
formul
administ
two
final
boost
week
respect
formul
alum
sa
carbopol
wait
period
week
fig
immun
respons
assess
fig
reciproc
neutral
titer
wane
week
interv
period
howev
singl
boost
alum
formul
increas
neutral
titer
week
five
level
p
titer
increas
second
immun
week
interestingli
adjuv
sa
carbopol
use
boost
elderli
mice
neutral
titer
increas
wane
respons
p
remain
lower
initi
respons
observ
young
mice
thu
elderli
mice
experienc
multipl
rsv
immun
young
mice
still
modest
level
serumneutr
activ
boost
respons
alum
adjuv
could
effect
achiev
threshold
level
protect
immun
investig
whether
sera
reactiv
preimmun
elderli
mice
direct
toward
prefus
specif
antigen
site
antigen
site
ii
present
pre
postfus
form
rsv
f
protein
fig
case
young
mice
explor
sitespecif
immun
respons
aid
probe
ko
mutat
antigen
site
b
post
f
probe
ko
mutat
antigen
site
ii
measur
bind
sera
week
post
immun
well
two
boost
post
f
site
ko
site
ii
ko
post
f
site
ii
ko
probe
use
bli
sera
respons
pre
post
f
probe
exhibit
profil
nearli
ident
neutral
titer
fig
also
observ
signific
fraction
respons
p
target
antigen
site
also
analyz
sera
elderli
mice
immun
qualiti
humor
respons
induc
alum
sa
carbopol
adjuv
formul
fig
interestingli
group
adjuv
formul
elicit
balanc
subclass
respons
pattern
expect
elderli
mice
immun
adjuv
sa
carbopol
retain
igg
subclass
respons
pattern
observ
young
mice
fig
hand
elderli
mice
immun
alumadjuv
elicit
strongli
skew
respons
observ
young
mice
instead
elicit
balanc
respons
ratio
boost
boost
sa
carbopol
alum
group
significantli
differ
correspond
time
point
week
pi
p
thu
igg
subclass
respons
pattern
appear
determin
prime
immun
c
adjuv
formul
induc
balanc
respons
mice
test
whether
high
titer
observ
adjuv
sa
carbopol
mice
also
higher
pref
stabil
bovin
rsv
f
mice
cattl
bovin
adjuv
poli
c
sa
carbopol
mixtur
use
immun
two
group
mice
two
immun
week
five
sera
significantli
higher
reciproc
neutral
titer
observ
sa
carbopol
group
compar
poli
c
group
geometr
mean
titer
respect
p
valu
fig
next
immun
cattl
bovin
adjuv
analog
water
oil
adjuv
isa
vg
isa
vgcarbopol
formul
rather
surprisingli
signific
differ
observ
neutral
titer
isa
vg
isa
vg
plu
carbopol
group
indic
combin
adjuv
significantli
enhanc
immun
respons
cattl
fig
vaccin
formul
includ
antigen
agonist
immun
system
antigen
present
cell
select
present
target
antigen
immun
system
greatli
influenc
immun
elicit
vaccin
adjuv
may
influenc
type
immun
profil
well
breadth
neutral
antibodi
persist
protect
respons
one
major
goal
vaccin
rsv
induc
immun
wide
rang
age
group
neonat
elderli
elderli
popul
experienc
repeat
rsv
infect
throughout
life
preexist
immun
boost
respons
neutralizationsensit
epitop
could
achiev
threshold
level
protect
immun
may
requir
formul
rsv
vaccin
differ
adjuv
undertook
compar
studi
adjuv
singl
immunogen
rsv
f
elderli
mice
studi
mice
significantli
higher
neutral
titer
observ
six
group
mice
immun
alum
sa
sa
carbopol
adjuplex
poli
c
poli
ic
lc
adjuv
agonist
mpla
alum
plu
mpla
addavax
wherea
unadjuv
titer
protect
threshold
fig
alum
surprisingli
exhibit
stronger
adjuv
effect
magnitud
antibodi
respons
mpla
alum
mpla
formul
even
though
alum
plu
mpla
formul
synergist
effect
adjuv
hpv
viruslik
particl
thu
immunogen
may
influenc
properti
concentr
dose
adjuv
also
combin
immunogen
adjuv
known
whether
specif
properti
alum
improv
respons
whether
agonist
like
mpla
way
interfer
respons
rsv
f
titer
prefusionf
specif
antibodi
shown
correl
magnitud
rsv
neutral
activ
human
sera
therefor
interrog
immun
sera
use
three
antigen
sitespecif
probe
fig
found
human
sera
highli
neutral
sera
poli
c
poli
ic
lc
sa
sa
carbopol
group
elicit
polyclon
respons
primarili
site
much
lesser
extent
site
ii
present
prefus
state
rsv
f
subclass
respons
reflect
respect
helper
helper
cell
bias
immun
respons
pattern
mice
interestingli
sa
sa
carbopol
poli
c
poli
ic
lc
group
induc
balanc
igg
respons
wherea
alum
mpla
alum
plu
mpla
adjuplex
addavax
induc
predominantli
respons
adjuv
group
high
neutral
titer
rsv
exhibit
balanc
respons
high
titer
neutral
antibodi
report
balanc
respons
mice
immun
reconstitut
virosom
produc
rsv
envelop
contain
lipopeptid
adjuv
contrast
respons
induc
adjuplex
balanc
respons
obtain
mice
immun
influenza
ha
protein
formul
adjuplex
elderli
mice
preexist
immun
boost
respons
alum
adjuv
could
achiev
high
level
protect
immun
wherea
sa
carbopol
adjuv
one
immun
necessari
achiev
similar
level
neutral
contrast
alum
adjuv
rsv
f
protein
elderli
balbc
mice
also
confer
protect
neutral
antirsv
f
antibodi
titer
albeit
protect
suboptim
compar
seen
young
mice
interestingli
alum
group
elderli
mice
respons
determin
prime
immun
mice
c
prime
boost
regimen
induc
balanc
pattern
thu
result
indic
rsv
f
vaccin
immun
respons
mice
influenc
properti
concentr
dose
adjuv
augment
combin
antigen
adjuv
adjuv
enabl
respons
result
higher
rsv
neutral
activ
mice
overal
data
support
fact
adjuv
play
less
role
determin
respons
follow
boost
preimmun
anim
induct
event
follow
primari
immun
addit
carbopol
oilinwat
adjuv
sa
enhanc
antibodi
respons
mice
addit
carbopol
waterinoil
adjuv
isa
vg
appear
enhanc
antibodi
respons
calv
overal
result
suggest
particular
differ
adjuv
may
speci
specif
furthermor
role
adjuv
context
rsv
immun
legaci
formalininactiv
rsv
firsv
vaccineenhanc
ill
consid
two
major
immunolog
pattern
associ
formalininactiv
rsv
firsv
vaccineenhanc
ill
one
poor
function
neutral
antibodi
nt
activ
despit
induct
signific
bind
antibodi
thought
contribut
immun
complex
deposit
small
airway
document
children
die
firsv
enhanc
respiratori
diseas
erd
second
pattern
cell
respons
associ
eosinophilia
neutrophil
alveol
although
possibl
suffici
nt
activ
induc
specif
respons
correct
control
cell
respons
pattern
adjuv
may
make
possibl
test
proteinbas
vaccin
neonat
difficult
regulatori
hurdl
dose
stabil
pref
antigen
reduc
low
level
induc
subprotect
antibodi
respons
possibl
simul
pattern
lung
inflamm
seen
full
dose
less
effect
vaccin
therefor
use
correct
conform
vaccin
antigen
redirect
antibodi
neutralizationsensit
site
may
suffici
even
adjuv
prevent
pathogen
inflammatori
respons
breakthrough
infect
pref
vaccin
antigen
deliv
protein
ultim
target
popul
pregnant
women
elderli
potenti
older
children
group
prime
natur
infect
role
adjuv
primarili
increas
magnitud
respons
base
establish
precursor
cell
b
cell
popul
pregnant
women
vaccin
avoid
excess
respons
safeti
concern
relat
pregnanc
adjuv
need
boost
antibodi
respons
protect
level
adult
alumbas
formul
may
accept
safeti
immunolog
profil
use
pregnanc
elderli
older
children
potent
toler
adjuv
chosen
base
result
earli
phase
clinic
trial
